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Background: Cutaneous allodynia (CA) is a common feature of migraine, which has a  complex 
underlying pathophysiology that is not well understood. In addition to pain, photophobia, 
 phonophobia, osmophobia, nausea, and vomiting, CA can contribute to the overall disability 
caused by migraine. The presence of CA can be established via a validated questionnaire. 
 Validated questionnaires and other tests are rarely performed in clinical practice. As such, 
 current prevalence estimates for CA may be an underestimation.
Methods: Utilizing a validated questionnaire, we assessed the presence of CA in consecutive 
patients (n=44) presenting with chronic migraine at a tertiary headache center.
Results: CA appears to be quite prevalent, at ∼90%, among female patients with chronic 
migraine.
Conclusion: CA prevalence in chronic migraine may be underestimated in the literature, and 
larger studies may better demonstrate a more accurate estimate of its prevalence.
Keywords: headache, validated questionnaire, migraine chronification, central sensitization
Background
Migraine is one of the most common headache disorders for which patients present 
to a physician for evaluation, with a prevalence of 18% in women and 6% in men.1,2 
Migraine is a primary headache disorder that probably occurs as a result of one or 
more variants in the genetic code.3 The exact mechanisms by which susceptibility is 
related to initiation of migraine attacks are not completely understood.
Cortical spreading depression (CSD) is a wave of neuronal hyperexcitation fol-
lowed by suppression that crosses neurovascular territories, and is thought to be the 
inciting event that triggers a migraine. CSD is also thought to be the cause of aura, and 
the gradual spread of CSD correlates with the gradual expanding nature of visual and 
sensory aura.4 CSD leads to vascular changes, release of inflammatory neuropeptides, 
and subsequent central sensitization.5,6
In addition to this cascade of excitatory events, in migraineurs, there may also 
be dysfunction of the descending central nervous system pathways, which normally 
function to inhibit nociceptive transmission.7 The periaqueductal gray, nucleus cunei-
formis, and rostral ventral medulla have all been implicated to varying degrees as being 
involved in descending modulation of nociceptive transmission.8
In rat models, it was found that inducing a single, high-intensity meningeal 
 nociceptive stimulation with an injectable inflammatory soup caused reversible cuta-
neous hypersensitivity.9 Similar reversible cutaneous hypersensitivity was generated 
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with repetitive, but not single, low-intensity stimulation. 
Fos expression, which can be a marker for neuronal activity, 
increased after a single high-intensity stimulation. Repeated 
high-intensity stimulation led to increase in neuronal hyper-
excitability, impairment of inhibitory pathways, increase in 
trigeminal central sensitization, and persistent cutaneous 
hypersensitivity.9
Central sensitization is thought to result in many features 
of migraine, including throbbing quality, photophobia, phono-
phobia, osmophobia, nausea, and vomiting. In addition to 
these features, many patients experience cutaneous allodynia 
(CA), which refers to nonnoxious skin stimulation causing 
an unpleasant or painful response. As such, the presence of 
CA can be a useful marker for central sensitization.
In rat models, the application of inflammatory soup on 
the dura with coadministration of sumatriptan effectively 
blocked the development of CA as the neuronal response 
threshold to skin stimulation did not decrease. In contrast, 
a 2-hour delay in sumatriptan administration caused the 
neuronal response to skin brushing to remain elevated after 
the development of CA.10
CA is not a part of the International Classification of 
Headache Disorders, Third Edition, Beta Version (ICHD-III 
Beta) criteria for migraine, and as such, the presence of CA 
is often not routinely assessed in clinical practice.11 Although 
currently not a part of the diagnostic criteria for migraine, 
the presence of CA may serve as a predictor of migraine 
chronification.
Prevalence estimates of CA have been variable across 
different populations. In a study conducted in United States, 
44  subjects with episodic migraine were tested for mechani-
cal and thermal pain thresholds in the absence of and during a 
migraine. Among the subjects, 79% were found to have CA.12
In another US study, 89 subjects with chronic migraine 
were tested for brush allodynia. Thirty-five patients were 
tested for allodynia while they were having an acute head-
ache exacerbation and 54 were tested when they had their 
baseline headache. In total, 38 patients (43%) exhibited 
brush allodynia.13
In a web based survey conducted in the Netherlands 
involving 2,331 migraineurs, 1,624 (70%) were found to 
have CA. Lifetime depression, female sex, low age of onset, 
and high migraine frequency were all risk factors for CA. 
In addition, CA was an independent predictor for increase 
in migraine frequency over a mean follow-up period of 
93±30 weeks (range: 26–160 weeks).14 On the basis of 
this study, CA appears to be a risk factor for migraine 
 chronification, and detecting the presence of CA may 
influence therapeutic decision making in terms of abortive 
and preventive treatment strategies. The gold standard for 
identification of CA is quantitative sensory testing (QST) 
performed both between and during attacks. This method of 
identification is time consuming and impractical for routine 
clinical use.
A validated questionnaire is a tool that can be utilized to 
determine the presence of CA. A 12-item questionnaire was 
devised to assess skin sensitivity during a migraine. This 
questionnaire has previously been validated by determining 
pain thresholds to mechanical and thermal stimulation using 
QST in the absence and presence of a migraine.15
The objective of this study was to estimate the prevalence 
of CA in a US population of subjects with chronic migraine at 
a tertiary headache center using a validated questionnaire.
Methods
This study was conducted at the Mayo Clinic, Rochester, 
MN. It was approved by the Investigational Review Board 
of the Mayo Clinic.
Consecutive patients diagnosed by a headache neurolo-
gist with chronic migraine were invited to participate in the 
study. Study neurologists assigned a headache diagnosis 
according to ICHD-III Beta criteria. Patients who provided 
written informed consent to participate were enrolled in the 
study. Subjects provided baseline data for the study at the 
enrollment visit.
Information was collected from all subjects at enrollment 
on demographic and headache characteristics, including age, 
sex, age of onset of migraines, and presence of aura. Subjects 
were classified as allodynic or not if they endorsed one or 
more items on a 12-item questionnaire designed to identify 
allodynia during a migraine.15 The questionnaire included 
12 questions. It assessed whether combing hair, placing hair 
into a ponytail, shaving, wearing eyeglasses, wearing contact 
lenses, wearing earrings, wearing necklaces, wearing tight 
clothes, taking a shower with water hitting the face, resting 
the face on a pillow on the side of the headache, heat expo-
sure, and cold exposure were painful or unpleasant during 
a migraine.15
Table 1 Demographic and clinical characteristics of subjects
Subjects, n=44
average age, years (range) 39.3 (18–63)
subjects with aura 17
Mean age of migraine onset 19
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Results
The baseline characteristics of the subjects are listed in 
Table 1. The breakdown of allodynia scores is presented in 
Figure 1. Only one subject chose not to continue in the study 
after enrolling, for personal reasons. Among 44  subjects, 
40 were found to have CA based on their validated question-
naire score.
Discussion
CA is a common feature of migraine and can be considered 
a clinical marker for central sensitization. As expected, 
migraineurs with CA have been noted to have lower  thermal 
pain thresholds on cutaneous testing during a migraine. 
Although this lower thermal pain threshold tends to improve 
between attacks, both episodic and chronic migraineurs tend 
to have a lower thermal pain threshold interictally 48 hours 
after their previous attack than nonmigraine controls. This 
interictal lower thermal pain threshold may increase the 
tendency to develop a migraine and may serve as an index 
of overall migraine activity.10
In a functional magnetic resonance imaging (MRI) study 
using blood oxygen-level-dependent (BOLD) contrast-
sensitive sequences, allodynic migraineurs tended to have 
more prominent periaqueductal gray and nucleus cuneiformis 
resting state connectivity with other brainstem, thalamic, 
insula, and cerebellar regions that process pain when com-
pared to migraineurs without prominent allodynia. Resting 
state  connectivity in allodynic migraineurs also tended to 
be stronger, with frontal and temporal regions suggesting 
differences in higher-order pain modulation.16
These thermal threshold and MRI BOLD imaging data 
further suggest that the presence of CA is probably a risk  factor 
for the transformation from episodic to chronic migraine, and 
detecting the presence of CA may influence therapeutic deci-
sion making in terms of abortive and preventive treatment 
strategies. On the basis of our data, CA appears to be quite 
prevalent, at ∼90%, in this chronic migraine US population. 
This may be in part due to the high potential sensitivity of 
the questionnaire utilized because a subject who could recall 
a single attack during which he/she found one of the items 
assessed as unpleasant would be labeled as having CA.
The lower prevalence estimates of CA in the literature 
may be in part due to the percentage of subjects having 
episodic migraine, the quality/intensity of sensory stimula-
tion used to trigger a response from the subject, as well as 
the variability among study populations that were involved. 
Larger studies may better demonstrate a more accurate esti-
mate of this prevalence. Future CA studies may also help 
better elucidate the ascending and descending central nervous 
system pathways, as well as the sequence of pathologic events 
that culminate in the form of central sensitization and the 
disabling features of migraine.
A weakness of our study was that it was conducted at a 
tertiary headache center, and the consecutive migraine sub-
jects who were enrolled all happened to be women, which 
limits generalizability. In addition, comorbidity data were 
not collected, which may have provided insight into what 
other conditions may predispose to CA in a chronic migraine 
population. The authors were unaware of Allodynia Symptom 
Checklist (ASC-12) scoring system17 at the time this study was 
conducted, which could have been used instead of the vali-
dated CA questionnaire. It is, however, unlikely that use of the 
ASC-12 would have altered the final results of this study.
Clinical implications
•	 The prevalence of CA among subjects with chronic 
migraine in this study was ∼90%, which is higher than 
the estimates for episodic and mixed episodic/chronic 
migraine populations.
•	 CA is probably a risk factor for the chronification from 
episodic to chronic migraine.
•	 CA is a marker for central sensitization, which has clini-
cal implications in terms of timing of abortive therapy 
administration and CA onset.
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Figure 1 Breakdown of allodynia scores.
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